Format

Send to

Choose Destination
J Neuroimmunol. 2014 Sep 15;274(1-2):38-45. doi: 10.1016/j.jneuroim.2014.06.012. Epub 2014 Jun 24.

Laquinimod exerts strong clinical and immunomodulatory effects in Lewis rat experimental autoimmune neuritis.

Author information

1
Department of Neurology, St. Josef Hospital, Ruhr-University of Bochum, Germany. Electronic address: kalliapit@yahoo.gr.
2
Department of Neurology, St. Josef Hospital, Ruhr-University of Bochum, Germany.
3
Teva Pharmaceutical Industries Ltd, 5 Bazel Street, Petah Tiqva 49131, Israel.
4
Department of Neurology, St. Josef Hospital, Ruhr-University of Bochum, Germany. Electronic address: ralf.gold@rub.de.

Abstract

Laquinimod is an immunomodulatory drug with neuroprotective potential. We used the animal model of experimental autoimmune neuritis (EAN) in the Lewis rat to study the effects of laquinimod treatment. After immunization with the neuritogenic peptide aa 53-78 of P2 myelin protein, preventive therapy with 12.5mg/kg laquinimod once daily inhibited neuritis in clinical and electrophysiological terms. Histology corroborated a lower degree of inflammatory lesions and demyelination in the sciatic nerve. The proportion of FoxP3-positive regulatory T cells in the peripheral lymph nodes of treated rats remained unchanged. We conclude that laquinimod may represent a therapeutic option in human autoimmune neuropathies.

KEYWORDS:

Autoimmune neuropathies; Autoimmunity; Experimental autoimmune neuritis; Immunotherapy; Inflammation; Laquinimod

PMID:
25005118
DOI:
10.1016/j.jneuroim.2014.06.012
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center